Back in 2013, Actelion launched Opsumit, a new-and-improved pulmonary arterial hypertension (PAH) drug it hoped would help make up sales for its aging Tracleer. And so far, everything is going according to plan.
The med pulled in CHF 147 million ($154 million) for the Swiss biotech in Q3, trumping the CHF 125 million analysts had predicted. “The launch momentum for Opsumit continues unabated,” CFO Andre Muller told Reuters.
It’s a good time for Opsumit to be hitting its stride. Sales of PAH predecessor Tracleer fell 17% to CHF 289 million for the period–about where analysts thought they’d be, the news service reports.
But with Opsumit picking up the slack, the company thinks it’s in good shape. It revised its growth forecast for the year, announcing that it now expects core earnings expansion to top 20%, up from the mid- to high-teens jump it last predicted.
As such, Actelion doesn’t “need M&A,” it’s CEO, Jean-Paul Clozel, told Reuters, pointing out that pickups were “not a fundamental aspect of our strategy.”
But that hasn’t kept the company out of many an M&A rumor. Back in September, it confirmed that it was in strategic talks with Texas’ ZS Pharma, and it’s in regular discussions with “7 or 8” companies over possible tie-ups. Actelion has the capacity to make a buy bigger than $2.5 billion, Muller said, though it won’t pull the trigger without good reason.
But Opsumit’s hot start could attract buyers, too. Earlier this year, word on the street was that deal-hungry Shire was eyeing a deal, sending Actelion’s shares up past CHF 147. Since then, though, Shire has made a play for young Baxter spinoff Baxalta, and Clozel told Reuters Actelion hasn’t been approached by shoppers.
By Carly Helfand
Source: Fierce Pharma
Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.
Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.
In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.